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Abstract Wound healing is a complex sequence of cellular
and molecular processes that involves multiple cell types
and biochemical mediators. Several growth factors have
been identified that regulate tissue repair, including the
neurotrophin nerve growth factor (NGF). As non-adenine
based purines (NABPs) are known to promote cell
proliferation and the release of growth factors, we investi-
gated whether NABPs had an effect on wound healing.
Full-thickness, excisional wound healing in healthy BALB/c
mice was significantly accelerated by daily topical applica-
tion of NABPs such as guanosine (50% closure by days 2.5–
2.8). Co-treatment of wounds with guanosine plus anti-NGF
reversed the guanosine-promoted acceleration of wound
healing, indicating that this effect of guanosine is mediated,
at least in part, by NGF. Selective inhibitors of the NGF-
inducible serine/threonine protein kinase (protein kinase N),
such as 6-methylmercaptopurine riboside abolished the
acceleration of wound healing caused by guanosine, con-
firming that activation of this enzyme is required for this
effect of guanosine. Treatment of genetically diabetic BKS.
Cg-m+/+lepr db mice, which display impaired wound
healing, with guanosine led to accelerated healing of skin
wounds (25% closure by days 2.8–3.0). These results
provide further confirmation that the NABP-mediated
acceleration of cutaneous wound healing is mediated via an
NGF-dependent mechanism. Thus, NABPs may offer an
alternative and viable approach for the treatment of wounds
in a clinical setting.
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Introduction
Healing of skin wounds is an essential process in the
response of tissues to injury. Although most wounds heal
rapidly, impaired or delayed tissue repair represents a major
clinical challenge. Most failed or delayed healing is
associated with some form of host impairment, such as
diabetes, infection, immunosuppression or vascular insuffi-
ciency [1, 2]. The biological processes in wound healing
occur in sequential phases, which include coagulation,
inflammation, tissue formation and tissue remodelling [3].
Injury to the skin is often associated with the extravasation
of blood from injured vessels. Platelet aggregation and
blood coagulation at the injury site initiate the healing
process, and the subsequent inflammatory stage starts with
the migration of polymorphonuclear neutrophils, followed
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regulated attraction of leukocytes is essential to ensure a
well-ordered inflammatory process that initiates tissue
repair. As repair and inflammation progress, new tissue is
formed, the extracellular matrix is rebuilt, and fibroplasia
and angiogenesis occur [4]. These steps progress in a
coordinated manner and require the presence of various
cytokines, growth factors and other bioactive molecules [3,
5–7]. Interruption at any point in this highly regulated
process results in impaired wound healing.
Previous studies have demonstrated that growth factors
synthesized by several cells of the healing wound promote
tissue repair [3, 5, 7], and topical application of growth
factors such as platelet-derived growth factor, or fibroblast
growth factor, or epidermal growth factor accelerate wound
healing [3, 5, 7, 8]. Nerve growth factor (NGF) is
considered to be particularly important in promoting tissue
repair; it regulates the survival and differentiation of
neurons [9, 10] and is important in wound healing, since
topical application of this neurotrophin has been shown to
improve the rate of wound healing in healthy mice [11–13]
as well as in genetically diabetic mice [12, 14]. In diabetic
animals the NGF content of the skin is reduced [12], and
this may contribute to the delayed repair of diabetic
wounds.
The first evidence that a small molecule may also
regulate the process of wound healing was shown by the
adenosine A2A receptor agonist, CGS-21680 (4-[{N-ethyl-
50-carbamoyladenos-2-yl}aminoethyl]phenylpropionic acid
[15]. This purine analogue activates the Gs-protein linked
adenosine A2A receptor, and, by increasing intracellular
cAMP [16], it accelerated wound healing in healthy mice as
well as in diabetic mice. More recently, these findings in
healthy mice were confirmed by the use of another highly
selective adenosine A2A receptor agonist, MRE0094
(2-[2-(4-chlorophenyl)ethoxy]adenosine [17]. It is interest-
ing to note that another adenosine analogue, cyclopentyla-
denosine (CPA), has also been reported to accelerate wound
healing [18]. This adenosine derivative is a highly selective
agonist at the adenosine A1 receptors, which inhibit
adenylyl cyclase synthesis and, thus, decrease intracellular
cAMP concentrations [16]. Extracellular ATP has also been
suggested as a potential mitogenic modulator of cells
involved in wound repair [19, 20], and, recently, Greig
and colleagues provided comprehensive evidence in sup-
port of an NGF-dependent role of purinergic receptors and
thus purinergic signalling [21, 22].
Besides adenosine analogues, non-adenine based purines
(NABPs), such as guanosine and inosine, also have potent
effects on growth and differentiation of a wide range of
cells [23–24]. These purines do not interact with adenosine
receptors, and their modes of action appear to be distinct
from those of the adenine-based compounds [23, 25, 26].
Non-adenine based purines exert a number of trophic
effects on cell proliferation and cell differentiation in a
variety of cell types [23–25, 27–30], including proliferation
of capillary endothelial cells (processes that are important
in wound healing). Some of these effects of guanosine are
mediated by activation of its high-affinity putative receptor
site expressed in rat brain membranes [26] and in cultured
rat astrocytes [31]. Other effects may be mediated by the
ability of guanosine to stimulate the release of trophic
factors from cells, including NGF [23, 25, 32]. As reviewed
above, NGF plays an important role in promoting wound
healing [11–14, 33, 34].
These findings led us to the hypothesis that non-adenine
based purines may enhance wound healing and do so
through mechanisms distinct from those mediated by
adenosine-based purines. The purpose of this study was to
determine whether non-adenine based purines had any
effect on healing of excisional dermal wounds in normal,
healthy mice. Since NGF production and wound healing are
impaired in diabetes [12, 14, 33], we also tested the effect
of non-adenine based purines on wound healing in
genetically diabetic mice.
Materials and methods
Study design
Normal, healthy, female mice 6–7 weeks old (BALB/c,
Charles River, Wilmington, Mass., USA; average blood
glucose level 6.0 mM) and female genetically diabetic mice
(BKS.Cg-m+/+lepr db, Jackson Laboratories, Bar Harbor,
Me., USA; average blood glucose level: 23.8 mM) were ob-
tained. Mice were housed in level B conditions (specific
pathogen free) at the Central Animal Facility (CAF) of
McMaster University on a 12 h light/dark cycle. On arrival,
animals were housed in groups and were acclimatized to
their surroundings for 6 days. All mice were given free
access to standard rodent chow and water. Animal care was
in accordance with the guidelines of the Canadian Council
on Animal Care and the McMaster University Animal
Research Ethics Board.
Excisional wound formation
Mice were anaesthetized with isoflurane (3–5%), O2
(1.5 l/min) in a level B surgical suite. Two sterile, full-
thickness, excisional wounds (1.0 cm in diameter) were
made on either side of the dorsum of mice, using a template
and surgical scissors [15]. Wounds were separated by a
minimum of 1.0 cm of unwounded skin. Mice were housed
individually after the wounds were made to prevent licking
and scratching by cage mates.
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Guanosine, guanine, guanosine triphosphate, 8-bromo-
guanosine, 7-methyl-guanosine, hypoxanthine, inosine,
6-thioguanine (6-TG), 6-methyl mercaptopurine riboside
(6-MMPR), 6-thioguanosine and all other agents used in
the study were purchased from Sigma (St. Louis, Mo.,
USA) unless otherwise stated. All purine analogues were
dissolved in 1 M NaOH and made to the required con-
centration by the addition of either distilled H2Oo r
phosphate-buffered saline (PBS); the pH of the solutions
was adjusted to pH 7.4 with 1 M HCl. Before use, drug
solutions were filtered through a 0.2 μm HT Tuffrym
membrane (Acrodize), and warmed to 37 °C. NGF and
neutralizing antibodies to NGF (25 μg/ml; anti-NGF) were
a generous gift from Dr. M.D. Coughlin, Department of
Medicine, McMaster University.
Treatment of wounds
In each experiment 4–7 mice were randomly assigned to
the different treatment groups. Most experiments were
repeated at least three times. Investigators who measured
the size of the wound were unaware of the treatment
groups. Wounds were treated by topical application of
either 20 μl 1.5% w/v carboxymethylcellulose (CMC) in
PBS (control) or 20 μl of one of the non- adenine based
purine analogues in CMC (1.5% w/v) at the same time each
day for 7–8 consecutive days following wounding. We
applied drug solutions topically to each wound by pipetting
the solution onto the wound surface and spread them
uniformly across the entire wound with the edge of the
pipette tip.
Determination of wound area
To facilitate accurate visualization of the wound margins
and to facilitate access of the test agents to the wound,
scabs were gently removed on days 4, 5, 6 and 7 after
wounding [18]. At the time the wounds were made, the skin
was easily stretched, so that the wound areas varied
considerably during measurement, making an accurate
assessment of wound size very difficult. To avoid the
potentially confounding effects of this variability, wound
outlines were traced onto thin transparent plastic sheets on
the day after the wounds were made, and this was defined
as day zero of the treatment period. Daily measurements
were then made in duplicate for 7–8 days. Because the
absolute rates of wound healing varied between groups of
mice, matched controls were performed for every experi-
mental group.
Quantification of wound area
Transparencies containing the tracings of the wounds were
scanned into an Apple iMac computer using an Agfa
scanner, and their segmentation was analysed and binarized
using IPLab software (version 3.5; Scanalytics, Inc.,
Fairfax, Va., USA). For each animal the area of the wound
was determined every day for a 7–8 day period, and this
was compared with the area of the wound on day zero of
the treatment period. The percentage of wound closure
(i.e., healing) was calculated for each experimental animal
in every treatment group by comparison of the mean values
of wound size determined at each time point to the day zero
values. The average wound closure within a group for each
day was plotted on a graph and was compared with that of
other treatment groups.
Histology
On days 1, 2, 3, 4 and 5 after wounding, mice were
euthanized by CO2 narcosis. Tissue samples, including the
entire wound area and underlying muscles of the body
flank, were dissected and fixed for 1 week in phosphate-
buffered 10% formalin. Each tissue sample was carefully
trimmed with a fresh razor blade to eliminate any
unwounded tissue. Tissues were dehydrated in increasing
concentrations of alcohol and xylene and embedded in
paraffin, and 0.5 mm thick sections were cut and mounted
on glass slides, stained with haematoxylin and eosin and
covered with a coverslip. All sections were examined under
a light microscope by an investigator who was unaware of
whether the sample was from a treated or a control group.
Statistical analysis
Wound areas, calculated as described above, were entered
into Microsoft Excel 2000. For each wound, differences
between the area on the first day and each subsequent day
were expressed as a percentage of the area for each animal
on day zero. Owing to the degree of variability observed
between groups of mice in the absolute rates of wound
healing, each experiment included its own vehicle control.
Results are presented as a percentage of wound area closed
over time or as the time required for each wound to reach
50% closure.
Percentage-of-wound-closure data were also transformed
into arcsin SQRT (percent) values, and the following
statistical analyses were performed. Data were analysed
by linear regression analysis, and the slopes and the
intercepts in the control group were compared with those
ofthevarioustreatmentgroups.Resultsfrom theeffectofthe
various treatments over time were analysed by a two-way
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test. P < 0.05 was considered statistically significant.
Results
Spontaneous healing of excisional dermal wounds
in healthy adult mice
We observed that, in healthy BALB/c mice, 1 cm diameter
excisional dermal wounds healed spontaneously, as has been
reported by others [15]. Therefore, in these experiments, we
studied the effects of treatments with non-adenine based
purines on the acceleration of wound closure.
Guanosine accelerates the rate of wound healing
in healthy adult mice
Excisional wounds of BALB/c mice were treated daily for
6–7 days with guanosine in 1.5% CMC in concentrations
ranging from 50 μM to 1,000 μM. Another group of mice
was treated with 1.5% CMC only (vehicle control) for the
same time, and the rate of wound healing was compared in
the two groups of mice. Guanosine (250 μM), administered
topically once daily, enhanced the rate of wound healing
compared to that of vehicle-treated controls (P < 0.001, n =
8, Figure 1). Other concentrations of guanosine (500 μM–
1,000 μM) had no significant effect on wound closure.
Twice-daily treatments with guanosine (250 μM) acceler-
ated wound closure to an even greater extent than a once-
daily application of guanosine. The effect of this treatment
was highly significant when compared with that of vehicle-
treated controls (P < 0.001, n = 10, data not shown).
Effect of guanosine on wound morphology
In the first 2 days after injury histological examination of
wounds in control mice showed a necrotic crust, averaging
100–400 μm in thickness, overlying a diffuse infiltration
of inflammatory cells. Beneath the dense layer of inflam-
matory cells the tissue was oedematous and contained
tissue exudates, indicating active inflammation. In contrast,
in guanosine-treated mice at 2 days, the necrotic crust was
much thinner, and the inflammatory response was much
less. There was very little oedema, and tissue ingrowth
beneath the layer of inflammatory cells was noticeable.
Many of the cells appeared to be spindle shaped, consistent
with the appearance of healthy fibroblasts. The matrix
tissue appeared to be more organized and compact in the
guanosine-treated wounds than in controls (Figure 2).
Histological examination of wounds treated with guanosine
revealed several marked differences from those treated with
vehicle alone, and may offer some clues to potential cellular
targets. Vehicle-treated wounds had substantially more
accumulation of fibrinous exudate under the superficial
crust, as well as a greater leukocytic infiltration within the
underlying muscle than did wounds that had been treated
with guanosine. The large accumulation of fibrinous
exudate is believed to be due to severe vascular damage
to the deep subcutaneous blood vessels at the time of skin
injury, with extravasation of plasma proteins, including
fibrinogen, within the first 2 days following surgery [4].
Infiltration of the fibrinous exudate by neutrophils is
considered an acute inflammatory response of the tissues
to injury, driven by a constant demand for neutrophils
during the formation and maintenance of the superficial
crust [4, 6]. The less pronounced accumulation of fibrinous
exudate in the guanosine-treated wounds at 2 days after
wounding coincided with reduced infiltration of the tissues
underlying the superficial crust and was temporally related
to the acceleration of wound closure.
Guanosine-induced acceleration of wound healing
is mediated by NGF
Cutaneous wound healing is promoted by several different
growth factors [8], including NGF [12, 13]. Guanosine [32]
and the hypoxanthine derivative, AIT-082 [35] have been
Figure 1 Guanosine accelerates the rate of wound healing in healthy
adult mice. Full-thickness, excisional, dermal wounds of healthy,
young, adult BALB/c mice were treated with guanosine (250 μM–
1,000 μM) or with 1.5% CMC, administered topically, once daily.
Areas of wounds were measured daily and quantified as described in
the Methods and materials section. Daily administration of guanosine
(250 μM) increased significantly the rate of wound healing compared
with that in vehicle-treated controls (mean ± SEM, n =8 ;P < 0.001).
Other concentrations of guanosine had no significant effect on wound
closure
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cultured astrocytes. We therefore questioned whether the
acceleration in wound healing observed in guanosine-
treated mice was mediated via NGF. As reported by others
[12, 13], we also found that daily application of 100 μg/ml
of the 2.5 S form of NGF to the wounds of the mice
increased the rate of wound healing compared to that of
CMC-treated controls (data n o ts h o w n ) .T r e a t m e n to f
wounds with guanosine (250 μM) accelerated wound
healing, as previously described (P < 0.05). Time required
for 50% closure in guanosine-treated wounds was
1.1 days (mean ± SEM, n = 10) compared with 1.7 days
in controls (mean ± SEM, n = 10) (Figure 3). Daily
treatment of wounds with the neutralizing antibody to NGF
(25 μg/ml) alone slowed the rate of wound healing
(Figure 3). Time required for 50% closure in the anti-
NGF-treated mice was 2.5 days. Daily co-treatment of
wounds with guanosine (250 μM) and the neutralizing
antibody to NGF (25 μg/ml) abolished the guanosine-
induced acceleration of wound healing, so time for 50%
wound healing was 1.7 days (mean ± SEM, n = 10;
Figure 3). These results indicate that, at least in part, NGF
mediates the acceleration of wound healing by guanosine.
Guanosine-induced acceleration of wound healing
is inhibited by 6-MMPR
In PC12 cells and peripheral neurons NGF has been
shown to promote neurite outgrowth by activating the
NGF-inducible protein kinase N, a partially characterized
serine-threonine kinase [36–38]. Benowitz et al. (in 1998)
[39] found that axon outgrowth in fish retinal ganglion cells
Figure 2 Effect of guanosine on wound inflammation. Sections of
skin wounds stained with haematoxylin and eosin 2 days after injury.
(a) Wound from mouse treated with vehicle control solution showed a
necrotic crust (NC, and arrow between lines) overlying a diffuse
infiltration of inflammatory cells (IF). Beneath the dense layer of
inflammatory cells the tissue was oedematous and contained tissue
exudates (ED), indicating active inflammation. (b) In contrast, in
guanosine-treated mice at 2 days, the necrotic crust (NC, and arrow
between lines) was much thinner, and the inflammatory response was
much less. There was very little oedema, and tissue ingrowth beneath
the layer of inflammatory cells was noticeable. Many of the cells
appeared to be spindle shaped, consistent with the appearance of
healthy fibroblasts (star). The matrix tissue appeared to be more
organized and compact in the guanosine-treated wounds than in
controls
Figure 3 Guanosine-induced acceleration of wound healing is
mediated by NGF. Full-thickness, excisional, dermal wounds of
healthy, young, adult BALB/c mice were treated with guanosine
(250 μM), or anti-NGF (25 μg/ml), or with guanosine (250 μM) plus
anti-NGF (25 μg/ml), or with 1.5% CMC, administered topically,
once daily. Areas of wounds were measured daily and quantified
as described in the Methods and materials section. Daily admin-
istration of guanosine (250 μM) increased significantly the rate of
wound healing compared with that of vehicle-treated controls.
Time required for 50% closure in guanosine treated wounds was
1.1 days (mean ± SEM, n = 10), compared with 1.7 days in controls
(mean ± SEM, n = 10). Daily treatment of wounds with anti NGF
slowed the rate of healing to 2.5 days (mean ± SEM, n = 10). Co-
treatment with guanosine plus anti-NGF prolonged the time required
for 50% wounds closure to 1.7 days (mean ± SEM, n = 10)
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kinase N is inhibited by the purine analogue, 6-TG
(apparent Ki = 6 μM[ 37]), and even more potently by
6-MMPR, (apparent Ki = 5 nM [40]). We therefore
examined whether 6-MMPR had any effect on guanosine-
induced acceleration of wound healing. Daily application of
6-MMPR (100 μM) alone had no significant effect on
wound healing (Figure 4). Treatment of wounds with
guanosine (250 μM) again increased the rate of wound
healing on days 1 through 5 (P < 0.02) (Figure 4). Time
required for 50% wound closure in guanosine-treated mice
was 2.0 days (mean ± SEM, n = 5) compared with 4.1 days
in controls (mean ± SEM, n = 5; Figure 4). Co-application
of guanosine (250 μM) plus 6-MMPR (100 μM) abolished
the acceleration of wound healing caused by guanosine
treatment. Time required for 50% wound closure in
guanosine plus 6-MMPR treated mice was 4.0 days
(mean ± SEM, n = 5; Figure 4). Similar effects were also
seen when wounds were co-treated with guanosine
(250 μM) plus 6-TG (1000 μM, data not shown). These
findings indicate that activation of the NGF-inducible
protein kinase N may, at least in part, contribute to the
guanosine-promoted acceleration of wound healing.
Guanosine accelerates the rate of wound healing
in genetically diabetic mice
In various animal models of diabetes NGF content of the
peripheral nerves is reduced, and this may contribute to the
impaired regeneration of the damaged tissue [41]. Recent
reports have also demonstrated that the NGF content in
wounds of diabetic mice is significantly reduced [33], and
that treatment of wounds of these mice with NGF
accelerates wound healing [12, 14]. Since our data in
normal mice implied that non-adenine based purines
accelerated wound healing via an NGF-dependent mecha-
nism, we therefore examined whether application of
guanosine to the wounds of genetically diabetic mice,
BKS.Cg-m+/+lepr db, had any effect on the rate of wound
healing. As reported by others [12], wounds of the diabetic
mice took longer to heal than those of normal mice treated
with 1.5% CMC (compare Figure 5 with other figures).
Topical application of guanosine (250 μM) once daily for
14 days enhanced the rate of wound healing in genetically
diabetic mice compared with that of vehicle-treated diabetic
mice in the first few days after injury (Figure 5). In
preliminary experiments, treatments were conducted for up
to 14 days, but, subsequently, it was determined that
differences between treated and control groups became
negligible beyond day 8, so experiments were shortened to
reflect this fact.
Time required for 25% wound closure in guanosine-
treated diabetic mice was 2.8–3 days (mean ± SEM, n = 18;
Figure 5) compared with 4 days in diabetic mice treated
with 1.5% CMC (mean ± SEM, n = 20; Figure 5). This
improvement was detected as early as 1 day after treatment,
was maximal over the first 2 days (P < 0.02) and was
sustained for up to 4 days (Figure 5).
Effect of non-adenine based purines on wound healing
in healthy adult mice
We also examined the effect of a number of other naturally
occurring purine derivatives, such as guanine, GTP, inosine,
hypoxanthine, and the synthetic guanosine analogues
8-bromo-guanosine and 7-methylguanosine, on the rate of
wound healing in healthy adult mice (Table 1). Treatment
of mice (n =5 –7) with each purine analogue was performed
as a separate experiment, with its own matched vehicle
control (1.5% CMC, n =5 –7). Daily application of guanine
(250–1,000 μM) to the wounds of healthy mice also
accelerated the rate of wound healing compared with that of
vehicle control. Time required for 50% wound closure was
2.2 days in guanine (250 μM)-treated mice versus 3.8 days
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Figure 4 Guanosine-induced acceleration of wound healing is
inhibited by 6-MMPR. Full-thickness, excisional, dermal wounds of
healthy, young, adult BALB/c mice were treated with guanosine
(250 μM), or with 6-MMPR (100 μM) or with guanosine (250 μM)
plus 6-MMPR (100 μM), or with 1.5% CMC, administered topically,
once daily. Areas of wounds were measured daily and quantified
as described in the Methods and materials section. Daily admin-
istration of guanosine (250 μM) increased significantly the rate
of wound healing compared with that of vehicle-treated controls.
Time required for 50% closure in guanosine-treated mice was
2.0 days (mean ± SEM, n = 5) compared with 4.1 days in controls
(mean ± SEM, n = 5). Daily application of 6-MMPR alone to the
wounds had no significant effect on healing time. Co-treatment of
wounds with guanosine (250 μM) plus 6-MMPR (100 μM) abolished
the guanosine-induced acceleration of wound healing. Time required
for 50% wound closure in guanosine (250 μM) plus 6-MMPR
(100 μM) treated mice was 4.0 days (mean ± SEM, n =5 )
656 Purinergic Signalling (2006) 2: 651–661in the control animals that received the CMC alone.
However, treatment of wounds with GTP, using a similar
concentration range, had only a slight effect. Daily
application of inosine (250–1,000 μM) to the wounds of
healthy young mice accelerated the rate of wound healing
compared with that of mice treated with CMC alone. Time
required for 50% wound closure was 1.2 days in inosine
(250 μM)-treated mice versus 2.8 days in the control
animals. Inosine-induced enhancement of wound healing
was reduced by co-application of inosine (250 μM) plus
6-MMPR (100 μM) or inosine (250 μM) plus 6-TG
(1,000 μM) (data not shown). These findings demonstrate
that the enhancement of wound closure by inosine is also
mediated by activation of the partially characterized NGF-
inducible serine-threonine kinase, protein kinase N. Treat-
ment of wounds with hypoxanthine (250 μM) also
accelerated the wound healing time. Time required for
50% wound closure was 2.4 days in hypoxanthine
(250 μM)-treated mice versus 3.25 days in the control
animals that received the CMC alone.
Wounds of healthy mice treated daily with the synthetic
guanosine derivative, 7-methylguanosine, had a reduced
healing time compared with mice treated with CMC alone.
Time required for 50% wound closure was 2.7 days in
7-methylguanosine (250 μM)-treated mice versus 4.0 days
in the control animals that received the CMC alone. In
contrast, daily application of 8-bromo-guanosine (250 μM)
to wounds had only a slight accelerating effect on wound
healing. Time required for 50% wound closure was 3.3
days in 8-bromoguanosine (250 μM)-treated mice versus
3.8 days in the control animals that received the CMC
alone.
Discussion
The present study is the first to report the effects of the non-
adenine based purine nucleosides, guanosine and inosine,
on the rate of wound healing in both normal and genetically
diabetic mice. The results demonstrate that topical applica-
tion of guanosine or inosine significantly increased the
Figure 5 Guanosine accelerates the rate of wound healing in
genetically diabetic mice. Full-thickness, excisional, dermal wounds
of genetically diabetic mice (BKS.Cg-m+/+lepr db) were treated with
guanosine (250 μM) or with 1.5% CMC topically, daily. Areas of
wounds were measured daily and quantified as described in the
Methods and materials section. Daily treatment of wounds with
guanosine (250 μM) accelerated the rate of healing compared with
that in vehicle controls. Time required for 25% wound closure in the
guanosine (250 μM)-treated diabetic mice was 3.0 days
(mean ± SEM, n = 18) compared with 4.2 days in mice treated with
vehicle only (mean ± SEM, n = 20)
Table 1 Effect of non-adenine based purines on wound healing in healthy adult mice. Full-thickness, excisional, dermal wounds of healthy,
young, adult BALB/c mice (n =5– 7) were treated with selected naturally occurring purines: guanosine, guanine, GTP, inosine, hypoxanthine or
the synthetic guanosine derivatives 8-bromoguanosine or 7-methylguanosine, all at (250 μM), administered topically, once daily for 7–8 days. For
each treatment group matched controls (n =5– 7) were treated with 1.5% CMC. Areas of wounds were measured daily and quantified as
described in the Methods and materials section. The rate of wound healing was accelerated by guanosine, guanine, inosine, hypoxanthine, and 7-
methylguanosine. GTP and 7-methylguanosine had no effect on wound closure. Results are presented as time required for 50% wound closure.
+ Accelerates wound healing, NE no effect.
Non-adenine based purine Treatments
a Control
b Effects
Guanosine 2.5–2.8 4.00 +
Guanine 2.20 3.80 +
GTP 3.35 3.10 NE
Inosine 1.20 2.80 +
Hypoxanthine 2.40 3.25 +
8-Bromoguanosine 3.30 3.80 NE
7-Methylguanosine 2.70 4.00 +
aAll non-adenine based purines were tested at 250 μM concentration.
bControl mice were treated with 1.5% CMC.
Purinergic Signalling (2006) 2: 651–661 657healing rate of wounds in young, healthy mice, as well as in
genetically diabetic mice.
Previous studies have focused on the effect of adenosine
analogues in wound healing. Cyclopentyladenosine, a
selective agonist of the A1 adenosine receptor, has been
reported to stimulate the proliferation of keratinocytes,
fibroblasts and endothelial cells, thereby promoting wound
healing [18]. CGS-21680, acting via A2A adenosine
receptors, has also been reported to enhance healing
through promoting fibroblast and endothelial cell migration
to the wound site [15]. Moreover, various P2Y and P2X
purinergic receptors responsive to ATP and to UTP have
been implicated in various aspects of wound healing [20],
including P2X5, P2X7, P2Y1 and P2Y2 [21, 22].
Although both adenosine and purinergic P2 receptors
have been found to have a role in wound healing, hitherto,
non-adenine based purines have not been known to play a
role. However, our data demonstrate that guanosine and
inosine may also accelerate wound healing. Each active
non-adenine based purine showed an inverted U-shaped
concentration-dependence curve. This is a common phar-
macological phenomenon. In previous studies we have
shown that several non-adenine-based purines that promote
cell proliferation in vitro at lower concentrations also inhibit
cell proliferation at higher concentrations [24, 25]. There-
fore it is not unexpected that there should be a similar
concentration-dependence curve in vivo.
The mechanism by which non-adenine based purines
accelerate wound healing appears to be unique. Since
neutralizing antibodies to NGF inhibited the effects of
non-adenine based purines, it appears that their ability to
accelerate wound healing was mediated through NGF.
Certainly, non-adenine based purines stimulate the release
of both NGF and other trophic factors from several types of
cells in tissue culture, including fibroblasts [25, 32] and
astrocytes [23]. So we postulate that guanosine may also
stimulate the release of NGF from cells when applied to
wounds in vivo. NGF promotes wound healing in healthy
mice [11–13], in genetically diabetic mice [12, 14, 33] and
in diabetic patients [42–44].
The precise mechanism by which NGF accelerates
wound healing is unknown. Although it was originally
assumed to be strictly a neurotrophin, it is now recognized
that NGF is produced by many types of cells, including
some that participate in wound healing [34], such as
fibroblasts [45–47], keratinocytes [48], endothelial cells
[49, 50] and mast cells [51]. It has also been reported
recently that NGF may regulate certain immune and
inflammatory responses in cells that participate in wound
healing. For example, NGF promotes survival and function
of immunocompetent cells, including neutrophils, eosino-
phils, mast cells, macrophages and lymphocytes [12, 34].
NGF, acting via its high affinity tyrosine kinase receptor A
(TrkA) [52, 53] also increases the migration of skin
fibroblasts [45, 46] and modulates proliferation of murine
[54] and human keratinocytes [55]. NGF has also been
shown to promote the proliferation of endothelial cells, and
increase angiogenesis, via the release of vascular endothe-
lial growth factor (VEGF) [49, 56].
One important part of the action of non-adenine based
purines in wound healing in relation to NGF appears to be
the interaction of non-adenine based purines with NGF-
inducible protein kinase N. Certainly, the nucleosides
inosine and guanosine are among the limited number of
purine nucleosides that activate NGF-inducible protein
kinase N, a partially characterized 47–49 kDa serine-
threonine kinase [37, 38, 40]. NGF-inducible protein
kinase N (PKN) is inhibited competitively by the purine
analog 6-thioguanine (6-TG) with an apparent Ki of 6 μM.
The effects of 6-TG are specific for PKN, as it has no effect
on other cellular signalling molecules such as protein
kinase A, protein kinase C, Ca
2+ calmodulin- or mitogen-
activated protein kinases, or the induction of several
immediate–early genes (e.g., c-fos) [37]. The purine ana-
logue 6-MMPR [40] also inhibits NGF-inducible protein
kinase N, but it is much more potent, with an apparent Ki of
5n M[ 40]. Both 6-TG and 6-MMPR inhibited the ability of
guanosine to promote wound healing. Together, these
findings indicate that both the release of NGF from cells
and the activation of the NGF-inducible protein kinase N
may contribute to the ability of non-adenine based purines
to accelerate wound healing.
One unexpected observation was the ability of guanine
to promote wound healing. Bases do not interact with
protein kinase N [37, 38, 40]. Therefore, one must postulate
a separate mechanism. One possibility is that the enzyme
purine nucleoside phosphorylase converts guanine to
guanosine. Another possibility is that guanine has an
entirely separate, and as yet undetermined, mechanism of
action. We are investigating these interesting possibilities.
The cellular responses involved in wound healing are
complex, making it difficult to determine the exact cellular
target of agents that promote wound healing. Nevertheless,
histological examination of wounds treated with guanosine
revealed several marked differences from those treated with
vehicle alone and may offer some clues to potential cellular
targets. It appears that guanosine may have reduced the
damage to the deep subcutaneous blood vessels, thereby
reducing fibrinous exudate resulting from vascular damage at
t h et i m eo fs k i ni n j u r y[ 4]. Guanosine also reduced
inflammatory neutrophilic infiltration of the fibrinous exu-
date [4, 6]. This suggests that guanosine, in some way,
reduced the inflammatory response. Macrophages also play
an important role early in wound healing; they are
responsible for producing cytokines that influence the
development of fibrinous exudate and neutrophilic infiltra-
658 Purinergic Signalling (2006) 2: 651–661tion of tissues [6, 57]. In in vitro studies, NGF has been
shown to activate the phagocytosis by murine macrophages
and increase the release of the inflammatory cytokine, IL-1β
[58]. Therefore, macrophages may be important cellular
targets through which guanosine and inosine accelerate
wound healing.
Previously, guanosine and inosine had been shown to
enhance proliferation of many cell types in cell culture,
including cerebral vascular endothelial cells, microglia and
astrocytes [24, 25]. Thus, one cellular mechanism by which
guanosine and inosine might accelerate wound healing is
by enhancing proliferation of cells involved in the process
of tissue repair. Data from the present study are compatible
with the hypothesis that the stimulation of proliferation of
fibroblasts and macrophages may also contribute to the
ability of inosine and guanosine to promote wound healing.
In diabetic animals NGF content of the peripheral nerves
[59] and target organs such as skin is reduced [33], and this
deficiency may contribute to the delayed repair of diabetic
wounds. Topical application of NGF to the wounds of dia-
betic mice has been reported to accelerate wound healing
[12, 14, 33]. A depletion of NGF content has also been
shown in human diabetics’ skin, and this was correlated with
a reduced number of keratinocytes [42]. Recent studies have
also demonstrated that topical application of NGF to human
diabetic pressure ulcers promoted the healing of skin ulcers
[43, 44] and improved the outcome of diabetic neuropathy
[60]. As Landi et al. [44] observed an increase in wound re-
epithelialization in the NGF-treated diabetic ulcers, they
suggested that NGF might act directly on the epithelium. In
addition, NGF may also promote tissue repair by increasing
angiogenesis by endothelial cells or by modulating the
inflammatory response in wound healing [44].
The present study was conducted using genetically
diabetic (BKS.Cg-m+/+leprdb) mice. These are clinically
relevant and reproducible models of impaired wound
healing [12, 14, 61]. Also like humans with adult onset
diabetes (BKS.Cg-m+/+leprdb), mice have markedly
delayed wound healing. They have, therefore, been used
to determine the potency of several agents to overcome
delayed tissue repair [12, 14, 61]. The fact that treatment
with non-adenine based purines accelerated wound healing
in these healing-impaired models offers the prospect of
significant enhancement to the quality of life for human
diabetes patients and at greatly reduced costs compared
with current therapies. These findings provide additional
support for the role of NGF in guanosine-induced enhance-
ment of wound healing.
The identification of likely molecular and cellular target
sites for non-adenine based purines indicates additional
potential therapeutic targets that may be exploited in wound
healing and in other physiological conditions that involve
macrophage and fibroblast resistance.
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